Summit Therapeutics Files 8-K on Financials

Ticker: SMMT · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1599298

Summit Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanySummit Therapeutics Inc. (SMMT)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.01, $410 million, $31.8 million
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-k, company-update

TL;DR

Summit Therapeutics dropped an 8-K on Jan 13th covering financials and other key updates.

AI Summary

Summit Therapeutics Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Miami, Florida.

Why It Matters

This 8-K filing provides crucial updates on Summit Therapeutics' financial health and operational status, which is important for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a standard 8-K reporting financial information and does not appear to contain any immediately concerning or high-risk disclosures.

Key Players & Entities

  • Summit Therapeutics Inc. (company) — Registrant
  • January 13, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • Miami, Florida (location) — Principal Executive Offices
  • Summit Therapeutics plc (company) — Former Company Name
  • Summit Corp plc (company) — Former Company Name

FAQ

What specific financial information is being reported in this 8-K filing?

The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details of these financial reports are not provided in the excerpt.

When was this 8-K report filed with the SEC?

The report was filed on January 13, 2025.

What is the principal business address of Summit Therapeutics Inc.?

The principal executive offices are located at 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.

Has Summit Therapeutics Inc. operated under any previous names?

Yes, the company was formerly known as Summit Therapeutics plc and prior to that, Summit Corp plc.

What is the SIC code for Summit Therapeutics Inc.?

The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 728 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2025-01-13 08:37:56

Key Financial Figures

  • $0.01 — ange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq Sto
  • $410 million — s Inc. (the "Company") was no less than $410 million. This included the repayment of outstan
  • $31.8 million — tanding principal and interest totaling $31.8 million from a related party loan that was prev

Filing Documents

02 Results of Operations and Financial Conditions

Item 2.02 Results of Operations and Financial Conditions. As of December 31, 2024, the preliminary unaudited balance of cash, cash equivalents, and short-term investment of Summit Therapeutics Inc. (the "Company") was no less than $410 million. This included the repayment of outstanding principal and interest totaling $31.8 million from a related party loan that was previously outstanding, as disclosed in the Company's Form 10-Q for the quarter ended September 30, 2024, filed on October 30, 2024. This amount is preliminary and is subject to completion of financial closing procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company's consolidated financial statements for the year ended December 31, 2024. In accordance with General Instruction B.2 of Form 8-K, the information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 13, 2025, the Company intends to present at the 43rd Annual J.P. Morgan Healthcare Conference. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01 as if fully set forth herein. In accordance with General Instruction B.2 of Form 8-K, the information set forth under Item 7.01 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Investor Presentation Slides made available on January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: January 13, 2025 By: /s/ Manmeet Soni Chief Operating Officer and Chief Financial Officer (Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.